In a report released yesterday, Ken Cacciatore from Cowen & Co. maintained a Buy rating on Revance Therapeutics (RVNC), with a price target of $55. The company’s shares closed yesterday at $17.07, close to its 52-week low of $16.56.
According to TipRanks.com, Cacciatore is a 1-star analyst with an average return of -1.5% and a 43.8% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Supernus Pharmaceuticals, and Alder Biopharmaceuticals.
Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $38.17, a 123.6% upside from current levels. In a report issued on February 14, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $34.55 and a one-year low of $16.56. Currently, Revance Therapeutics has an average volume of 456.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.
